Kenvue Inc. (KVUE): what the price requires

At today's price, Kenvue Inc. (KVUE) is priced for -2.8% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/KVUE

Headline

FieldValue
TickerKVUE
CompanyKenvue Inc.
Current price$19.21/sh
CompositionSelf Care 42% / Skin Health and Beauty 27% / Essential Health 31%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed8.1%
Operating margin today17.3%
Margin compression implied-9.2pp
Implied growth-2.8%
Multiple paid17x operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 7.2% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~7.2pp.

Reconcile: at the x-ray's 9.3% required return this reads ~11.1%/yr; the models below use their own rates.

How unusual the bet is: within-range

ReferenceValue
vs own history+0.08σ
cohort percentile (of 69 peers)35
implied end-window share0%

Valuation X-Ray

The price is justified by relative-multiple; asset-based/earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.88x5expensive
Earnings1.94x5expensive
Relative0.93x5justifies
Growth1.34x4expensive

Families that justify the price: Relative Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.0%); the inversion above states its own rate.

Per-Model Detail (n=19)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$10.621.81xyesFCF base $1.8B, growth 0% (input: historical growth), terminal g 0.5%, WACC 9.0%, 5yr projection
DCF Exit MultipleGrowth$17.161.12xyesExit EV/EBITDA: 9.8x / 11.8x / 13.8x (bear / base = today's held flat / bull), 5yr
Relative ValuationRelative$20.680.93xyesP/E 22x (static sector reference · 2026-04), scenarios: 18.6x / 22.0x / 25.4x (bear / base = reference held flat / bull), EV/EBITDA 14x
Simple DDMGrowth——no—
Two-Stage DDMGrowth$29.370.65xyesStage 1: 20% for 5yr, Stage 2: 3.5% perpetual
Simple Excess ReturnAsset$9.122.11xyesBV/sh $5.52, ROE (TTM) 15.3%, ke 9.3%
Two-Stage Excess ReturnAsset$11.591.66xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$12.371.55xyesRev $15.3B, growth 0% (input: historical growth; tapered), Terminal P/S: 2.0x / 2.4x / 2.8x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$10.081.91xyesEPS $0.84, growth 2% (input: historical EPS growth), PEG=11.38 (Overvalued)
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$11.331.70xyesNormalized EBIT (4y avg op income, one-time charges added back) $2.87B × (1−29%) / WACC 9.0% → EPV (no growth)
Residual IncomeAsset$11.861.62xyesBV $5.52 + 5yr PV of (ROE (TTM) 15.3% − Kₑ 9.3%) × BV; BV grows 8.8%/yr
Graham NumberAsset$10.211.88xyes√(22.5 × EPS $0.84 × BVPS $5.52) — Graham's conservative floor
EV/EBITDA RelativeRelative$22.870.84xyesEBITDA $3.19B × sector EV/EBITDA 14.0x
FCF YieldEarnings$9.911.94xyesFCF $1823.0M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$9.232.08xyesSBC-adj FCF $1.70B (FCF $1.82B − SBC $0.12B) capitalized at Kₑ
Ben Graham FormulaEarnings$27.100.71xyesEPS $0.84 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset$2.946.53xyesBV $5.52 × (ROIC 4.8% / WACC 9.0%)
P/Sales SectorRelative$15.911.21xyesRevenue $15.29B × sector P/S 2.0x
PEG Fair ValueRelative$31.500.61xyesEPS $0.84 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$9.082.12xyesEPS $0.84 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$7.6b
Net debt / NOPAT (after-tax)4.06x
Net debt / operating income (pre-tax)2.87x
Interest coverage6.2x
Share count CAGR (dilution)2.9%
Burning cashno

Bullet Takeaways

Bull Case

Kenvue is best understood at its current stage as a defensive consumer-health portfolio in the middle of a corporate transformation, where the bull case rests on brand durability and a pending acquisition. The 10-K states plainly that Kenvue is "the world's largest pure-play consumer health company by revenue with $15.5 billion in Net sales in the fiscal year 2024," and that scale sits behind brands consumers reach for by name. Its skin and hair portfolio alone includes "Neutrogena, Aveeno, Dr.Ci:Labo, OGX, Le Petit Marseillais, Lubriderm, and Rogaine," and its self-care shelf carries Tylenol and Listerine. The 10-K is explicit that "Our ability to compete successfully depends on the strength of our brands," and decades of consumer trust in those names is the moat that does not erode in a quarter.

The operating story has stabilized, which the bull case needs after a rocky stretch. First-quarter 2026 net sales were about $3.9 billion with net income of $474 million and earnings per share from continuing operations of $0.25, and management pointed to a second consecutive quarter of net and organic sales growth alongside year-over-year improvement in gross margin, operating margin, and EPS. A consumer-staples business returning to organic growth after a period of share loss is the inflection that matters, and the margin recovery suggests the execution is following.

The acquisition is the dominant catalyst and the clearest support for the price. Kimberly-Clark has agreed to combine with Kenvue in a deal valued in the tens of billions, shareholders have approved it, and a proxy advisory firm recommended in favor, with closing expected in the second half of 2026. For a holder, that reframes the investment: the upside is no longer purely about Kenvue executing a multi-year turnaround on its own, but about a deal closing at agreed terms. The balance sheet supports the standalone case in the meantime, with net debt near $7.6 billion against interest coverage above six times, comfortable for a stable cash-generative portfolio. Against consumer-health and household peers Haleon, Church and Dwight, Clorox, and Procter and Gamble, Kenvue's brand depth is competitive, and the pending combination is the bull's anchor.

Bear Case

The external variable with the most leverage on Kenvue is regulatory and legal, and it sits on the single product the company is most known for. A lawsuit accusing Kenvue of misleadingly marketing Tylenol by not disclosing an alleged autism risk to unborn children survived the company's motion to dismiss, meaning the litigation proceeds. Tylenol contributes an estimated 12% to 15% of earnings, so an adverse legal outcome, or even a sustained reputational hit, strikes at a material slice of the business. The 10-K already lists exposure to "claims, lawsuits, and regulatory and governmental investigations involving various issues such as product liability, labeling, marketing, advertising," and warns that "damage to our reputation or our brands could adversely affect us." When the company's competitive edge is brand trust, a public controversy over safety is the most dangerous kind of risk it can face.

The litigation overhang also complicates the deal that the bull case leans on. A pending acquisition is only worth its agreed terms if it closes on those terms, and a large, open-ended legal liability is exactly the kind of issue that can pressure a price, trigger a renegotiation, or extend the timeline. The investor buying today is underwriting both the legal outcome and the deal's completion, two separate risks stacked on each other, and the gap between the current price and the agreed deal value is the market's own estimate of how likely the deal is to close cleanly. That spread is not free money; it is compensation for the chance that the autism litigation or a regulatory review derails or reprices the combination.

The standalone business, absent the deal, is no growth engine. The price embeds essentially flat-to-declining operating profit over the coming years, and the inversion reads the implied trajectory as a modest decline, which tells you the market does not expect organic growth to do the heavy lifting. Net debt near $7.6 billion is serviceable at current coverage, but it is leverage on a business whose two consecutive quarters of organic growth are modest and recent rather than established. If the Kimberly-Clark deal were to fall through, the holder would be left with a leveraged, slow-growth consumer-health company carrying an active Tylenol liability and a portfolio that had been losing share before the recent stabilization. The bear case is that the price today is mostly a bet on a deal closing, and the things that could stop it, the litigation and any regulatory scrutiny of a roughly $40 billion consumer-staples combination, are precisely the risks outside the company's control.

Valuation

The price is making a deal-completion bet far more than a fundamental-growth bet. At today's level the market pays roughly 16 times Kenvue's operating income, and the inversion reads the implied trajectory as a modest decline of a few percent a year rather than growth, which is the market pricing a mature, slow-moving consumer-health portfolio. On standalone fundamentals alone, this is a value-supported name in the lower half of its peer multiple range, not a premium one. But standalone fundamentals are not what sets the price right now; the pending Kimberly-Clark acquisition is.

The method families read the way they do for a stable, brand-heavy staple. The relative-multiple lens supports the price, while the asset-value and earnings-power lenses read it as somewhat expensive, sitting above where book value and a single year's capitalized earnings land. That is the normal posture of a consumer-products company whose worth lives in brand equity and recurring demand rather than in tangible assets, so the asset lens structurally reads low. The peer-multiple lens supporting the price, with Kenvue in the lower half of its cohort range, says the standalone business is reasonably valued against household and consumer-health peers, not stretched.

The real valuation question is the deal arbitrage, and solvency frames it. Net debt near $7.6 billion is about three times operating income with interest coverage above six times, sound for a cash-generative portfolio and not a constraint on either the standalone case or the combination. The price today sits in relation to the agreed Kimberly-Clark terms, and the gap between them is the market's discount for completion risk, principally the Tylenol litigation and any regulatory review. A street consensus near a Hold with a mean target around $19 to $20 sits modestly above today's price, consistent with a deal expected to close but not certain. The honest read is that this is no longer primarily a fundamental valuation; it is a wager on whether a roughly $40 billion combination closes on its agreed terms, with the legal overhang as the chief variable that could change the answer.

Catalysts

The single dominant catalyst is the Kimberly-Clark acquisition. The combination is valued in the tens of billions, shareholders have approved it, a leading proxy advisory firm recommended in favor, and management is working toward completing the combination in the second half of 2026. Every other development is now secondary to whether and when that deal closes on its agreed terms, and the closing window is the catalyst the stock keys on.

The Tylenol litigation is the catalyst that cuts the other way. A lawsuit alleging Kenvue failed to disclose an alleged autism risk from acetaminophen use in pregnancy survived a motion to dismiss, so the case proceeds, and Tylenol contributes an estimated 12% to 15% of earnings. Any material legal ruling or regulatory action is a high-stakes event both for the standalone earnings base and for the completion of the acquisition. The interplay between the deal timeline and the litigation is the tension to watch over the next two quarters.

The underlying operating results give the standalone business a steadier footing. First-quarter 2026 net sales were about $3.9 billion with EPS from continuing operations of $0.25, and management cited a second consecutive quarter of net and organic sales growth with year-over-year improvement in gross and operating margin. The sell side sits at a Hold consensus with a mean price target near $19 to $20, modestly above today's price, consistent with a market that expects the deal to close but is pricing the completion and litigation risk into the gap.

Peer Cohorts (Per Segment, With Filing Citations)

Self Care (reported)

Skin Health and Beauty (reported)

Essential Health (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Kenvue FY2024 10-K · Kimberly-Clark acquisition announcement and shareholder vote, 2026 · Tylenol litigation coverage, 2026 · Kenvue Q1 2026 results, 2026 · Kimberly-Clark acquisition and shareholder vote, 2026 · MarketBeat and TipRanks analyst consensus, 2026

View the full interactive KVUE report on boothcheck